Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Assembly Biosciences, Inc. - Common Stock (NQ:ASMB)

30.77 +0.36 (+1.20%)

Streaming Delayed Price Updated: 10:45 AM EDT, May 12, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	13,840
Open	30.19
Bid (Size)	30.28 (100)
Ask (Size)	30.96 (200)
Prev. Close	30.41
Today's Range	30.15 - 30.99
52wk Range	12.11 - 39.70
Shares Outstanding	52,121,309
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

May 11, 2026

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

May 07, 2026

From Assembly Biosciences, Inc.

Via GlobeNewswire

Performance

YTD	-8.8%	-8.8%
1 Month	+5.2%	+5.2%
3 Month	+14.4%	+14.4%
6 Month	-4.0%	-4.0%
1 Year	+149.2%	+149.2%

More News

Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026

April 09, 2026

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights

March 19, 2026

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs ↗

December 22, 2025

Via Stocktwits

Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

December 22, 2025

From Gilead Sciences, Inc.

Via Business Wire

Assembly Biosciences Inc (NASDAQ:ASMB) Fits the Minervini Trend Template with Strong Growth Fundamentals ↗

December 15, 2025

Via Chartmill

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in

December 08, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Inc (NASDAQ:ASMB) Fits the Minervini Trend Template with High Growth Momentum ↗

November 24, 2025

Via Chartmill

Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

November 10, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

November 07, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

Forecasting The Future: 4 Analyst Projections For Assembly Biosciences ↗

October 14, 2025

Via Benzinga

Assembly Biosciences Announces Upcoming Investor Conference Participation

October 14, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

October 10, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗

September 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 08, 2025

Via Benzinga

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

August 08, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

August 08, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

August 06, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

August 06, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

July 26, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

June 30, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

June 25, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

May 27, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

May 08, 2025

From Assembly Biosciences, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Assembly Biosciences, Inc. - Common Stock publicly traded?

Yes, Assembly Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Assembly Biosciences, Inc. - Common Stock trade on?

Assembly Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Assembly Biosciences, Inc. - Common Stock?

The ticker symbol for Assembly Biosciences, Inc. - Common Stock is ASMB on the Nasdaq Stock Market

What is the current price of Assembly Biosciences, Inc. - Common Stock?

The current price of Assembly Biosciences, Inc. - Common Stock is 30.77

When was Assembly Biosciences, Inc. - Common Stock last traded?

The last trade of Assembly Biosciences, Inc. - Common Stock was at 05/12/26 10:45 AM ET

What is the market capitalization of Assembly Biosciences, Inc. - Common Stock?

The market capitalization of Assembly Biosciences, Inc. - Common Stock is 1.60B

How many shares of Assembly Biosciences, Inc. - Common Stock are outstanding?

Assembly Biosciences, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.